Pharmaceuticals, Biotechnology & Life Sciences

Explore how Bayer’s $7.25 bn Round Up settlement, looming Supreme Court review, and new $2.45 bn therapeutic acquisition reshape its legal risk, debt profile, and investor outlook.

Novo Nordisk faces a cyber‑extortion claim yet its obesity drugs stay strong—see how the breach impacts data security, FDA scrutiny, and Wegovy’s China launch.

Shanghai Fosun Pharmaceutical secures GMP certification and launches Phase IIb trial, boosting pipeline momentum amid sector sell‑off and highlighting strategic growth prospects.

Reckitt’s board revamp, Innoviva‑Dr. Reddy antibiotic partnership, and biopharma’s dual IPO‑acquisition trend illustrate how pharma firms are reshaping governance, accelerating AMR solutions, and strengthening pipelines ahead of key patent cliffs.

Discover how Natera’s board expansion, equity incentive plan boost and shareholder approvals reinforce governance, talent retention and investor confidence in biotech.

Agilent’s pre‑market jump hides more than momentum—life science growth, diagnostic demand, AI opportunities, and ESG‑driven risk mitigation shape its future.

Julia Haller’s insider share purchase shows confidence in Bristol‑Myers Squibb, while the PD‑L1 assay market is set to double, offering investors and clinicians new growth and precision‑oncology opportunities.

Mid‑June, Sartorius AG’s shares rose modestly, reflecting its resilient TecDAX position and long‑term biotech supply‑chain growth.

Merck KGaA leads the growing laboratory‑filtration market with advanced membrane tech that boosts purity, cuts costs, and aligns with evolving reimbursement models.

Johnson & Johnson’s strategic playbook: stabilizing stock amid market volatility, expanding medical‑device robotics, countering patent cliffs, and leveraging tiered pricing and M&A for long‑term growth.